Last updated on February 2018

Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer


Brief description of study

Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible.

Investigators initiated this multicenter two-armed phase III prospective trial to analyse the non-inferiority of hypofractionation with simultaneous integrated boost in patients with early breast cancer in comparison to standard fractionation.

Detailed Study Description

Control Arm:

Conventionaly fractionated radiotherapy of the breast 28 1.8 Gy = 50.4 Gy followed by a tumor bed boost sequentially 5 to 8 2.0 Gy = 10.0 Gy to 16.0 Gy, total dose 60.4 Gy to 66.4 Gy.

or Conventionaly fractionated radiotherapy of the breast 28 1.8 Gy = 50.4 Gy with simultaneous integrated boost to the tumor bed, total dose 28 0.3 Gy or 0.45 Gy= 8.4 Gy or 12,6 Gy, total dose 58,8 Gy to 63.0 Gy.

or Hypofractionated radiotherapy of the breast 16 2.66 Gy = 42.56 Gy followed by a tumor bed boost sequentially 5 to 8 2.0 Gy = 10.0 Gy to 16.0 Gy, total dose 52.56 Gy to 58.56 Gy.

Experimental Arm:

Hypofractionated radiotherapy of the breast 16 2.50 Gy with simultaneous integrated boost to the tumor bed, total dose within the boost volume 16 3.00 Gy.

Clinical Study Identifier: NCT02474641

Contact Investigators or Research Sites near you

Start Over

Robert Krempien, Prof.

HELIOS Klinikum Berlin-Buch, Strahlentherapeutische Klinik
Berlin-Buch, Germany
5.34miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.